Dosing & Administration

Dosing and Administration for Ustekinumab Are the Same as for STELARA® (ustekinumab)1,2

CD or UC

Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

PsA

Adults With Active Psoriatic Arthritis

PsO

Adults With Moderate to Severe Plaque Psoriasis

Pediatric

PsA or PsO

Pediatric Patients With Active Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis

Recommended Dosage for Adults With Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Intravenous Induction Adult Dosage Regimen
A single intravenous infusion dose of Ustekinumab administered over at least 1 hour using the weight-based dosage regimen specified in the table below.

Initial Intravenous Dosage of Ustekinumab

Body Weight* of Patient at the Time of DosingDoseNumber of 130 mg/26 mL
(5 mg/mL) Ustekinumab Vials
55 kg or less260 mg2
More than
55 kg to 85 kg		390 mg3
More than
85 kg		520 mg4

*Approximately 2.2 pounds per kilogram.

Subcutaneous Maintenance Adult Dosage Regimen
The recommended maintenance dosage is a subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

Administration

  • Please refer to the Dosage and Administration section of the Prescribing Information for complete information on how to prepare and administer Ustekinumab
  • Ustekinumab is intended for use under the guidance and supervision of a healthcare provider with patients who will be closely monitored and have regular follow-up
  • Patients may self-inject with Ustekinumab after healthcare provider approval and proper training
  • Patients should be instructed to follow the direction provided in the Medication Guide

References: 1. Ustekinumab [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.